Business Context and Reporting Period
Company: aTyr Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 6, 2020
Event: Entry into a Material Definitive Agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of the lead clinical candidate ATYR1923 for interstitial lung diseases (ILDs) in Japan.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial results. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
- Upfront Payment: $8 million to be received by aTyr Pharma.
- Potential Milestone Payments: Up to an additional $167 million contingent on development, regulatory, and sales milestones.
- Royalties: Tiered royalties ranging from mid-single digits to mid-teens on net sales in Japan.
Material Changes
The primary material change is the execution of the Collaboration Agreement with Kyorin. Under this agreement:
- Kyorin receives exclusive rights to develop and commercialize ATYR1923 in Japan for ILDs.
- Kyorin assumes responsibility for funding research, development, regulatory, marketing, and commercialization costs in Japan.
- aTyr Pharma retains responsibility for supplying drug product for Japan and acting as the global development leader.
Outlook, Risks, and Contingencies
Agreement Terms and Termination:
- Term: Continues until the expiration of royalty obligations (earlier of patent expiration, generic entry, regulatory exclusivity expiration, or 10 years after first commercial sale).
- Termination Rights: Kyorin may terminate for any reason with 90 days' written notice after the first anniversary of the effective date. Either party may terminate for breach, insolvency, or IP challenges.
Risks and Contingencies:
- Future payments are contingent upon achieving specific milestones; there is no guarantee these will be met.
- The agreement is subject to termination by Kyorin after one year without cause.
Investor Verification Checklist
- Verify the receipt of the $8 million upfront payment in subsequent cash flow statements.
- Monitor the status of ATYR1923 clinical trials to assess the likelihood of achieving the $167 million in milestone payments.
- Review the full Collaboration Agreement filed as an exhibit to the Form 10-K for detailed royalty tiers and termination clauses.
- Confirm aTyr Pharma's continued role as the global development leader and its ability to supply drug product for Japan.